International Edition
Latest News
Health

PSC-IBD Endoscopic Surveillance Gaps and a Pragmatic Pathway

Three major hepatology societies now align on annual colonoscopy and imaging for primary sclerosing cholangitis with inflammatory bowel disease, yet the Swedish SUPRIM cohort found that strategy detected cholangiocarcinoma at a median survival of only 13 months. The…

PSC-IBD Endoscopic Surveillance Gaps and a Pragmatic Pathway

Three major hepatology societies now align on annual colonoscopy and imaging for primary sclerosing cholangitis with inflammatory bowel disease, yet the Swedish SUPRIM cohort found that strategy detected cholangiocarcinoma at a median survival of only 13 months.

The American Association for the Study of Liver Diseases, the European Association for the Study of the Liver and the British Society of Gastroenterology agree that magnetic resonance cholangiopancreatography should replace diagnostic ERCP and that colonoscopy begins at PSC diagnosis, not at first bowel symptom, Cureus reported. Their consensus stops short of proving that surveillance improves long-term outcomes.

“This strategy did not detect cancer early enough to support long-term survival,” the SUPRIM investigators wrote of their prospective programme that followed 512 unselected patients with annual contrast-enhanced MRI/MRCP and CA 19-9. Over five years, 11 patients (2%) developed cholangiocarcinoma and two (0.5%) developed high-grade biliary dysplasia. Severe or progressive duct changes on imaging carried a hazard ratio of 10.50 (95% CI 2.49–44.31) for the composite of high-grade dysplasia or hepatobiliary malignancy.

Guidelines diverge on CA 19-9. AASLD permits annual imaging with or without the marker, while EASL does not recommend its routine use, citing limited specificity and frequent elevation during bacterial cholangitis or biliary obstruction. The 2025 EASL guideline on extrahepatic cholangiocarcinoma updated the classification and diagnostic work-up of perihilar and distal disease.

Diagnosis shifts from ERCP to MRCP

Contemporary guidance is explicit that ERCP should not be used to diagnose PSC. A systematic review and meta-analysis found a threefold increase in 30-day post-procedural cholangitis odds (OR 3.26, 95% CI 1.08–9.90) despite antibiotic prophylaxis in most patients. AASLD replaced the radiologically defined “dominant stricture” with the clinically anchored “relevant stricture” — any biliary or hepatic duct stricture accompanied by signs or symptoms of obstructive cholestasis or bacterial cholangitis.

Before scheduling ERCP, the endoscopist should answer which of three questions the procedure will settle: whether obstructive cholestasis or cholangitis requires drainage, whether malignancy is suspected and tissue is needed, or whether neither applies and the procedure should not proceed.

Colonoscopy underused at PSC diagnosis

Guidelines recommend ileocolonoscopy with biopsies in every patient with newly diagnosed PSC and no known IBD, repeated at roughly five-year intervals until IBD is identified. Histological colitis is frequently present without symptoms. Registry data show this recommendation is followed in only about four-fifths of eligible patients even in well-resourced systems.

The colitis of PSC-IBD is characteristically extensive but quiescent. Pancolitis predominates, and rectal sparing and backwash ileitis are over-represented relative to ordinary ulcerative colitis.

Phenotype uncouples bowel and biliary activity

Symptom burden is a poor guide to either colonic neoplastic risk or hepatic progression. Paradoxically, the presence of IBD appears prognostically favourable for the liver. These paediatric findings should be extrapolated to adults with caution.

Only approximately 2–8% of patients with IBD develop PSC, whereas most patients with PSC have IBD.

Tissue acquisition and UDCA

For suspected cholangiocarcinoma, guidelines endorse ERCP with brush cytology and fluorescence in situ hybridisation, adding cholangioscopy with targeted biopsy where available. Ursodeoxycholic acid is not recommended at high dose; low-to-moderate dose is optional. Biochemical response should not be used to justify dose escalation.

Pathway for centres without on-site transplant

Its explicit aim is to appraise the evidence behind each endoscopic decision in PSC-IBD and translate that evidence into a care pathway deliverable by gastroenterology services where transplantation requires external referral.

The American Association for the Study of Liver Diseases was incorporated in Illinois on March 23, 1950, by a group of leading specialists that included Hans Popper, Leon Schiff, and Sheila Sherlock. The organization played a seminal role in establishing hepatology as a recognized discipline and in founding other hepatological societies worldwide. It now comprises more than 5,000 members and hosts The Liver Meeting, the largest global scientific conference on liver diseases.

The review searched PubMed/MEDLINE and Embase, prioritising guidelines, randomised trials, systematic reviews and prospective multicentre cohorts. Study selection was performed by the first author and agreed upon by all authors; each reference was verified against its digital object identifier and PubMed record.

About the author: Health Desk

Health Desk at Archynewsy.